ArticleNPJ genomic medicine2021
The landscape of driver mutations in cutaneous squamous cell carcinoma.
Article in NPJ genomic medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 1 synthesis or guideline pooled it, 124 citations in OpenAlex.
- Sunburn and Cutaneous Squamous Cell Carcinoma: A Meta-Analysis.JAMA dermatology · 2025Pooled it
- Toward next-generation therapeutic HPV vaccines: A review on expanding the antigen repertoire and an integrated bioinformatics selection framework.Human vaccines & immunotherapeutics · 2026Review
- Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas.Molecular oncology · 2026Article
- A Prospective Study of Definitive ChemoRadiation With ImmunOtherapy (CRIO) in Locally or Regionally Advanced, Unresectable Cutaneous Squamous Cell Carcinoma.Advances in radiation oncology · 2026Article
- Comprehensive molecular characterization of cutaneous squamous cell carcinoma reveals determinants of metastatic progression.medRxiv : the preprint server for health sciences · 2026Article
- Article
- Oncogenic Ras drives EED degradation and PRC2 dysfunction to promote aggressive squamous cell carcinoma.Nature communications · 2026Article
- Skin Cancer Predisposition Genes, Full-Body Skin Examinations, Familial Disclosure, and Genetic Testing Among High-Risk Individuals.International journal of dermatology · 2026Article
- CIT tumor lines: A series of immunogenic murine cutaneous squamous cell carcinoma cell lines derived from chemical carcinogenesis.JID innovations : skin science from molecules to population health · 2026Article
- Recurrence and Metastasis in Cutaneous Squamous Cell Carcinoma: Clinicopathological Predictors From a 15-Year Single-Center Experience.Journal of clinical practice and research · 2026Article
- Renaissance of farnesyltransferase inhibitors in cancer.Journal of translational medicine · 2026Review
- The Dutch cutaneous squamous cell carcinoma and metastasis (D-SQUAME) study: a nationwide discovery cohort and nationwide validation cohort with nested case-control designs for risk prediction modeling.European journal of epidemiology · 2026Article
- Article
- CDKN2A, ITGA3, SMAD4 and SIRT7 gene expression in human cutaneous squamous cell carcinoma development and pre-clinical diagnosis.BMC cancer · 2026Article
- Article
- Progression patterns and clinical outcomes in patients with cutaneous squamous-cell carcinoma following anti-PD-1 therapy failure.ESMO open · 2026Article
- Precision Diagnosis in Cutaneous Head and Neck Squamous Cell Carcinoma.Biomedicines · 2026Review
- The oncogenome of the domestic cat.Science (New York, N.Y.) · 2026Article
- Genomic Insights into Cutaneous Squamous Cell Carcinoma.Cancers · 2026Article
- Identification of Basement Membrane-Related Biomarkers in the Progression of Cutaneous Squamous Cell Carcinoma.International journal of molecular sciences · 2026Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Cutaneous squamous cell carcinoma is a form of skin cancer originating from keratinocytes in the skin. It is the second most common type of cancer and is responsible for an estimated 8000 deaths per year in the United States. Compared to other cancer subtypes with similar incidences and death tolls, our understanding of the somatic mutations driving cutaneous squamous cell carcinoma is limited. The main challenge is that these tumors have high mutation burdens, primarily a consequence of UV-radiation-induced DNA damage from sunlight, making it difficult to distinguish driver mutations from passenger mutations. We overcame this challenge by performing a meta-analysis of publicly available sequencing data covering 105 tumors from 10 different studies. Moreover, we eliminated tumors with issues, such as low neoplastic cell content, and from the tumors that passed quality control, we utilized multiple strategies to reveal genes under selection. In total, we nominated 30 cancer genes. Among the more novel genes, mutations frequently affected EP300, PBRM1, USP28, and CHUK. Collectively, mutations in the NOTCH and p53 pathways were ubiquitous, and to a lesser extent, mutations affected genes in the Hippo pathway, genes in the Ras/MAPK/PI3K pathway, genes critical for cell-cycle checkpoint control, and genes encoding chromatin remodeling factors. Taken together, our study provides a catalog of driver genes in cutaneous squamous cell carcinoma, offering points of therapeutic intervention and insights into the biology of cutaneous squamous cell carcinoma.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.